Nectar Lifesciences Secures Ukraine GMP Nod for Unit VI, Valid Through April 2026

Nectar Lifesciences Ltd., a leading manufacturer of cephalosporin antibiotics and pharmaceutical formulations, has received Good Manufacturing Practice (GMP) certification for its Unit VI facility from Ukraine’s State Medical Drugs Control (SMDC). The certification, granted after a detailed inspection, is valid until April 18, 2026, and marks a significant milestone in the company’s efforts to expand its global footprint in regulated markets.

The certified facility, located in Barotiwala Industrial Estate near Baddi, Himachal Pradesh, is dedicated to manufacturing cephalosporin drug products. The approval reinforces Nectar’s position as a reliable contract manufacturing partner and opens new avenues for exports to Eastern Europe and CIS countries.

Key Highlights of the Certification

- Ukraine’s SMDC granted GMP certification to Nectar Lifesciences Unit VI  
- The certification is valid until April 18, 2026  
- Unit VI specializes in cephalosporin solid dosage forms including tablets, capsules, and dry powder suspensions  
- The approval enables Nectar to supply drug products to Ukraine and other SMDC-recognized jurisdictions  
- The inspection covered manufacturing practices, documentation standards, and quality control systems  

Strategic Significance of the Approval

1. Expansion into Eastern European Markets  
   - Ukraine’s GMP certification is a prerequisite for pharmaceutical exports to the region  
   - Nectar can now bid for government tenders and private contracts in Ukraine’s healthcare sector  
   - The approval may facilitate entry into neighboring markets with mutual recognition agreements  

2. Strengthening Global Compliance Credentials  
   - The certification adds to Nectar’s portfolio of international approvals, including USFDA, PMDA Japan, ANVISA Brazil, and COFEPRIS Mexico  
   - It demonstrates adherence to stringent quality and safety standards across multiple geographies  
   - The company’s reputation as a reliable contract manufacturing organization (CMO) is further reinforced  

3. Enhancing Operational Visibility  
   - Unit VI is one of Nectar’s key formulation facilities, equipped with automated systems and in-house utilities  
   - The GMP nod validates the company’s investments in infrastructure and process excellence  
   - It may lead to increased utilization of Unit VI and improved economies of scale  

Industry Context and Competitive Landscape

- The global demand for cephalosporin antibiotics remains robust, driven by rising antimicrobial resistance and hospital-acquired infections  
- Regulatory approvals from emerging markets are increasingly critical for Indian pharma companies seeking diversification  
- Nectar competes with other mid-sized Indian manufacturers in the contract manufacturing and export space  
- The company’s integrated operations and backward linkages offer cost advantages and supply chain reliability  

Recent Regulatory Challenges and Mitigation

- Nectar’s API facility in Saidpura, Punjab, was recently flagged by European regulators for compliance issues  
- The company received seven observations, including four critical, during a joint inspection by EDQM and AEMPS  
- A Corrective and Preventive Action (CAPA) report has been submitted, and a re-inspection is expected  
- The Ukraine GMP certification for Unit VI signals continued progress in maintaining global standards despite isolated setbacks  

Investor Sentiment and Outlook

- The certification is expected to boost investor confidence in Nectar’s regulatory resilience and export potential  
- Shares of the company have shown moderate recovery following recent regulatory disclosures  
- Analysts view the approval as a positive development that may support revenue growth in FY26 and FY27  
- Future performance will depend on successful resolution of EU observations and sustained compliance across facilities  

Conclusion

The GMP certification from Ukraine’s SMDC for Nectar Lifesciences’ Unit VI marks a strategic win for the company, enabling access to new markets and reinforcing its global manufacturing credentials. As the company navigates regulatory challenges and expands its international footprint, the approval serves as a testament to its commitment to quality, compliance, and operational excellence.

Sources: CNBCTV18, India Infoline, Nectar Lifesciences Official Website.